CRBP — Corbus Pharmaceuticals Holdings, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1595097 ·
Last close
$3.01
Market Cap
$62.03M
52W High
$12.88
52W Low
$2.81
ADV30
1,090,628
Next earnings
2026-11-10
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -38,824,000 -37,754,000 122,902,000 30,246,000 38,144,000
Jun 2026 0 — -36,190,000 -35,037,000 126,988,000 23,370,000 24,748,000
Mar 2026 0 — -24,304,000 -22,969,000 144,480,000 25,661,000 18,138,000
Dec 2025 0 — -21,966,000 -20,555,000 168,195,000 28,492,000 20,692,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-92,357,000
Investing CF
$-6,868,000
Financing CF
$95,979,000
CapEx
$-27,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.10
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-651,190,000
Inventory
—
Receivables
—
ST Investments
$85,091,000
EBIT TTM
$-119,873,000
Pretax Income TTM
$-116,315,000
Interest Exp TTM
$0
Analysts
9

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -85,310,000 -78,537,000 168,195,000 20,692,000 147,503,000 -64,491,000
Dec 2024 0 -48,721,000 -40,209,000 155,879,000 13,451,000 142,428,000 -41,794,000
Dec 2023 0 -45,078,000 -44,604,000 28,272,000 35,177,000 -6,905,000 -36,100,000
Dec 2022 0 -34,835,445 -42,346,903 66,311,940 33,321,923 32,990,017 -37,544,435
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-101,903,000
OpCashFlow TTM
—
Assets (Latest)
$126,988,000
Forward EPS
$-5.19

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $4.00 · spot: $2.74 · call volume: 61 · put volume: 106
Expected Move to 2026-12-18: ±$2.32 (84.52%) — implied range $0.42 – $5.06 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ACRV Acrivon Therapeutics, Inc. $61.28M $1.43 —
FBIO Fortress Biotech, Inc. $60.70M $1.82 —
KZIA KAZIA THERAPEUTICS LTD $60.68M $5.31 —
LFVN Lifevantage Corp $60.62M $4.78 —
RANI Rani Therapeutics Holdings, Inc. $64.61M $0.56 —

News headlines (Yahoo Finance, 1h cache)

Corbus Pharmaceuticals Starts Phase 3 Cancer Study, Weighs Next Steps for Obesity Drug
2026-11-18 11:12 · Yahoo
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
2026-11-16 13:00 · Yahoo
Corbus Pharmaceuticals: Q3 Earnings Snapshot
2026-11-10 13:16 · Yahoo
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
2026-11-10 13:00 · Yahoo
Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data
2026-11-09 23:14 · Yahoo
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
2026-11-05 13:00 · Yahoo
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
2026-10-22 12:00 · Yahoo
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
2026-09-29 12:00 · Yahoo
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
2026-09-15 08:02 · Yahoo
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
2026-09-14 13:28 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.